

Review

Cell cultures as model systems in breast cancer research

Radostina Alexandrova^{1*}, Desislav Dinev¹, Iva Gavrilova-Valcheva² and Ivan Gavrilov²

Abstract

¹Institute of Experimental Morphology, Pathology and Anthropology with Museum, Bulgarian Academy of Sciences, Acad. Georgi Bonchev Str., Block 25, Sofia 1113, Bulgaria

²University Specialized Hospital for Active Treatment in Oncology, Sofia, 6 Plovdivsko Pole Str., Sofia, Bulgaria

*Corresponding Author's Email:
rialexandrova@hotmail.com
Tel. +3592-979-3678

Despite undoubted success in early diagnosis and treatment of breast cancer, it remains one of the most common and lethal neoplastic diseases in the world among women. Adequate model systems, including cell cultures, can help us better understand breast cancer biology as well as for the discovery of new diagnostic, prognostic and therapeutic strategies. This review summarizes some of the main characteristics of cell cultures (primary cell cultures and immortal cell lines; 2D and 3D cell cultures) used in current biomedical research and their strengths and weaknesses.

Keywords: Primary cell cultures and immortal cell lines; 2D and 3D cell cultures, breast cancer

INTRODUCTION

The challenges of breast cancer research

Cancer is a group of related complex diseases characterized by uncontrolled cell division – the cells are insensitive to growth control signals, replicate limitlessly and avoid apoptosis. In addition, tumor cells have the potential to invade the surrounding tissue and/or spread to other parts of the body, which is often fatal (Hanahan, Weinberg, 2011). Cancer treatment becomes complicated because malignant cells are not pathogens that have specific treatments, but are the body's own cells that must be killed or physically removed (Levi et al., 2001). Different obstacles prevent successful therapy of neoplastic diseases such as tumor heterogeneity, (multi)drug resistance, side / toxic effects, and limited knowledge of the molecular and cellular biology of tumor cells.

Malignant neoplasms are the second cause of death, after heart diseases, and it is estimated to rank first beginning with 2010 (American Cancer Society, 2011). Worldwide 14.1 million (in Europe 3.4 million) new cases

were diagnosed as cancer in 2012, and it caused death for 8.2 million (1.75 million in Europe) people (Ferlay et al., 2012; Torre et al., 2012).

Globally, breast cancer (BC) is the most frequently diagnosed cancer in women, with an estimated 25% (1.7 million) new cases and 15% (more than 0.5 million) of deaths from all cancers every year (Torre et al., 2012).

Awareness of breast cancer, public attentiveness, and advancement in early diagnosis and treatment (including targeted anticancer therapy with monoclonal antibodies and/or tyrosine kinase inhibitors) has led to significant progress in screening and diagnosing BC as well as increasing five-year survival rate (Akram et al., 2017). Although enormous progress has been made over the last decades, the mobility of breast cancer is still increasing and associated with relative high mortality and high economic and social costs (Ferlay et al., 2010; Eccles et al., 2013; Asif et al., 2016). It is worthwhile to mention here that overall mortality has decreased by only 30% with > 90% sensitivity of current breast cancer screening approaches (Longacre et al., 2016).

Table 1. Breast cancer subtypes and permanent cell lines established from them

Subtype	Characterization	Permanent cell lines (examples)
Luminal A	ER positive PR high Ki-67 low (<14%) HER2 negative	MCF-7 HCC1428 EFM19 T47D
Luminal B (HER2 negative)	ER positive Either Ki-67 high or PR low HER2 negative	
Luminal B (HER2 positive)	ER positive Any PR Any Ki-67 HER2 over-expressed or amplified	BT474 UACC812 ZR7530 MDA-MB-361
HER2 positive	ER and PR absent HER2 over-expressed or amplified	SKBR3 SUM190PT SUM225CWN HCC1954 HCC1569 HCC202 AU565
Basal like / Triple negative	ER and PR absent HER2 negative	BT20 HCC38 HCC1143 HCC1395 MDA-MB-231 MDA-MB-157 MDA-MB-435 SUM52PE SUM149PE SUM229PE

According to Neve et al., 2006; Chavez et al., 2010; Subik et al., 2010; Holliday, Speirs, 2011; Goldhirsch et al., 2011; Inic et al., 2014; Dai et al., 2017.

ER - estrogen receptor, PR - progesterone receptor; HER2 - human epidermal growth factor receptor 2.

Breast cancer subtypes

Breast cancer displays intra- and inter-tumor heterogeneity due to genetic and non-genetic alterations. As a result it is presented by a spectrum of different subtypes with distinct biological features that lead to variations in response to various treatment modalities, tendency to metastasis, prognosis and clinical outcomes [Alexandrova et al., 2001; Holliday, Speirs, 2011; Koren, Bentires-Alj, 2015; Dai et al., 2017]. As such, breast cancer heterogeneity is one of the most important and clinically relevant areas of research.

Classification of breast cancer was based on the following main criteria: histological type, tumour grade, lymph node status, the presence / absence of hormonal (estrogen and / or progesterone) receptors and human epidermal growth factor receptor 2 (HER2), expression of Ki67, a marker of proliferation. The development of immunohistochemical techniques and molecular biological methods enable a deeper study of the variety of forms in breast cancer and facilitate their identification. The St. Gallen International Expert Consensus 2011 proposed a classification system for breast cancer to divide into five subgroups (Luminal A; Luminal B – HER2

negative; Luminal B – HER2 positive; HER2 positive and Basal like / Triple negative), that was further refined [Goldhirsch et al., 2011; Inic et al., 2014; Dai et al., 2017]. A brief description of these breast cancer subtypes is summarised in Table 1. Each subtype may in turn be subdivided into different forms. For instance, triple negative breast cancer (TNBC) is presented by at least four subtypes, i.e., core basal, claudin-low, metaplastic and interferon-rich breast cancer, each with distinct molecular characteristics and clinical behavior (Chavez et al., 2010; Dai et al., 2017).

Cell cultures as experimental models in cancer research

One of the greatest challenges standing in front of modern science is the necessity adequate experimental models to be created, which allow us to perform studies on the biology of tumor cells, the mechanisms of cancerogenesis, recurrence / metastasis, drug resistance, as well as testing innovative treatment approaches and identification of new markers for early diagnosis.

Table 2. Advantages and disadvantages of permanent cancer cell lines and primary cell cultures

Permanent cell lines (PCL)	
Advantages	Disadvantages
<ul style="list-style-type: none"> • Cost effective • Easy to handle • Can provide large number of cells • Avoid ethical concerns associated with the use of animal and human tissue • More homogenous as compared to PCC • Suitable for studies in different biomedical scientific fields (including cancer research and oncopharmacology) as well as for the needs of biotechnology (production of vaccines, monoclonal antibodies, biologically active substances) and tissue engineering (for example cyto- / biocompatibility assessment of new materials for bone implants and wound dressings) 	<ul style="list-style-type: none"> • Establishment of PCL is not easy, with low success rate • Often differ genetically and phenotypically from their tissue of origin due to continuous propagation in laboratory conditions • Possible contamination with cells from other cell lines • Risk of mycoplasma contamination that can persist undetected in cell cultures for a long period of time and can affect gene expression and cell behavior • The establishment of PCL may eliminate some types of cancer initially present in the original tissue samples • One and the same PCL cultured in different laboratories and/or under different conditions, may evolve into distinct modifications
Primary cell cultures (PCC)	
<ul style="list-style-type: none"> • Still express many of the important markers and functions seen <i>in vivo</i> and represent better the cells of origin • Can be useful to test whether proposed therapies for the particular cancer patient will be effective – the hallmark of personalized cancer treatment • Avoid problems of misidentification, contamination or other artefacts that accompany long-term cell cultures • Application in tissue engineering and regenerative medicine 	<ul style="list-style-type: none"> • The isolation process makes PCC vulnerable to contamination by bacteria or stromal cells • More heterogenous than PCL • More sensitive • Slow growth rates that make large-scale studies with PCC difficult • Short life • Often require additional nutrients not included in classical commercial media or even special media customized for each cell type

According to Alge et al., 2006; Pan et al., 2009; Alston-Roberts et al., 2010; Lorsch et al., 2014.

Animal models closely recapitulate *in vivo* human physiology and are important in cancer research, however their application is associated with ethical concerns; it is not clear whether they can fully predict human disease outcome; they are also consuming more money, time and resources. Furthermore, patient derived human cancer xenografts experience mouse-specific tumor evolution when implanted in immuno-suppressed mice (Carranza-Rosales et al., 2018; Byrne et al., 2017).

Primary cell cultures (PCC, cells, isolated directly from animal or human tissue, without cell proliferation *in vitro*) and especially immortal cell lines (PCL, cells that have been continually propagated in laboratory conditions over a long period of time - over 80-100 passages, immortalized through spontaneous mutations or genetic manipulation) have been successfully applied in various fields of biomedical research and biotechnologies. Some of the main advantages and weaknesses of PCL and PCC as well as of two-dimensional (2D, monolayer) and 3D cell cultures are summarized in Tables 2 and 3.

The first human cell line (HeLa) was established from cervical carcinoma over 60 years ago by George Gey and named after Henrietta Lacks, the woman from whom the tumor tissue was obtained [Gey et al., 1952; Scherer et al., 1953]. Since then it is widely accepted that PCL

play important role in our understanding of cancer and have been used extensively in the discovery and characterization of new antineoplastic drugs. For example, due to its highly sensitive to hormone through expression of estrogen and progesterone receptors MCF-7 cell line (Luminal A type breast cancer) has been useful for the study of the estrogen signaling pathway and the development of efficacious anti-hormonal therapies such as tamoxifen [Levenson, Jordan, 1997; Osborne, 1998]. The antitumor effect of the anti-HER-2 mouse monoclonal antibody (which was later humanized to create trastuzumab / herceptin) as a single agent and in a combination with chemotherapeutic agents, demonstrated in breast cancer cell lines that could amplify HER-2. Thus, it opened the door for clinical trials of trastuzumab (Hudziak et al., 1989; Pietras et al., 1994; Pegram et al., 1999; Sliwkowski et al., 1999). Furthermore, HER2-amplified cell lines (such as SKBR3 and HCC1954) are helpful to study mechanisms of resistance to anti-HER2 therapies and to search for new agents/strategies that can restore cancer cell sensitivity to the treatment (D'Alesio et al., 2017; Baldassarre et al., 2017).

The molecular profiles of a large number of human cancer cell lines are available in the Cancer Cell Line

Table 3. Advantages and disadvantages of 2D- and 3D-cell cultures

2D cell cultures	
Advantages	Disadvantages
<ul style="list-style-type: none"> • Less expensive and easier to maintain • A lot of literature available • Well established • Easier environmental control • Easier observation and measurement -can be conveniently analyzed by almost any kind of imaging 	<ul style="list-style-type: none"> • Decreased compatibility with living organisms • Not representative of real cell environment • Lack of predictivity
3D cell cultures	
<ul style="list-style-type: none"> • More physiologically relevant and predictive cell models • Allow interactions between different types of cells • Reduce the application of animal models • Provide more realistic way to grow and treat tumor cells 	<ul style="list-style-type: none"> • More expensive and difficult to maintain • Many 3D culture techniques are cumbersome and time-consuming and are not suitable for drug development screening and research • Challenges in microscopy and measurement due to the larger size as compared to 2D cell cultures • Diffusional transport limitations • Culture dependent alterations in gene expression

According to Edmondson et al., 2014; Katt et al., 2016.

Encyclopedia (Barretina et al., 2012), and these profiles can be compared to the profiles of a large number of human tumors, compiled as part of the Cancer Genome Atlas Research Network (Holliday and Speirs, 2011; Cancer Genome Atlas Research Network et al., 2013; Domcke et al., 2013; Katt et al., 2016).

The principles of good laboratory practice should be kept while working with cancer cell cultures. Following these regulations will ensure the safety of staff and the achievement of reliable results.

Among the problems associated with cell culturing are:

- i) Mycoplasma infection (resistant to commonly used antibiotics and invisible to the naked eye) is among the main problems in cell culturing. It has been estimated that about 5 to 30% of the world's cell lines are contaminated with mycoplasmas (Nikfarjam, Farzaneh, 2012).
- ii) The cell cultures can be contaminated with other cells. For instance evidences suggest that HeLa cells contaminated and overgrew other cell lines. Cultures, supposed to be of breast cancer or mouse origin, were proved to be HeLa cells (Lucey et al., 2009).

We must keep in mind that *in vitro* cultured cancer cells may undergo different genetic and epigenetic alterations. For example, Schmidt et al. reported the loss of estrogen and progesterone receptors in cultures breast cancer cells, derived from pleural effusion (Schmidt et al., (2007).

Breast cancer cell lines – past, present and future

The first breast cancer cell line (BT-20) was established in 1958 from a 74-year old Caucasian female [Lasfargues, Ozzello, 1958]. Various breast cancer cell lines were obtained in the next years including the “MD Anderson series” presented by nineteen human breast carcinoma

cell lines derived from pleural effusions (16 cell lines), brain metastases (two cell lines) and pericardial fluid (one cell line) [Cailleau et al., 1978]. “HCC series” cell lines were isolated at Hamon Cancer Centre [Gazdar et al., 1998]. Another popular and widely used cell line – MCF-7 (acronym of Michigan Cancer Foundation-7), was established in 1970 from breast adenocarcinoma of a 69-year-old Caucasian woman (Soule et al., 1973). The list includes also the immortal cell lines derived from breast primary tumours, pleural effusions or various metastatic sites in individual patients [Vandewalle et al., 1987; Minafra et al., 1989; Bover et al., 1991; Ethier et al., 1993; Zoli et al., 1997]. Many of these cell lines are now widely available through commercial cell banks – some of them are presented in Table 1.

The establishment of new breast cancer immortal cell lines continues to be an important challenge for biomedical professionals because of the following reasons:

- i) Relatively low number of BC cell lines are available at the moment – there are < 100 cell line available until today (Holliday, Speirs, 2011). The establishment of a new cancer cell line is not an easy task mainly because of technical difficulties in extracting viable tumor cells from the surrounding stroma, the problems accompanying long-term propagation during cultivation in laboratory conditions and at least in some countries (for example in the United Kingdom partly due to ethical restrictions concerning the use of human tissues for research (Holliday, Speirs, 2011; Dai et al., 2017).

- ii) A wide range of BC cell lines are needed to cover the full spectrum of breast cancer development and progress as well as inter-tumoral heterogeneity including cell lines from normal mammary tissue, premalignant breast formations, different (including rare) subtypes of breast cancer and ideally metastases from all major sites

as well as relapsed BC cell lines (Eccles et al., 2013). Most of the known BC cell lines (including those established from “good prognosis” subtypes such as luminal A) are obtained from metastases or pleural effusions due to the higher adaptability and durability of more aggressive (metastatic) cells. As a result, currently, there is no cell line to resemble adequately the good prognosis luminal A subtype - the most frequently diagnosed breast cancer subtype in women (Neve et al., 2006; Holliday, Speirs, 2011; Prat et al., 2013, Dai et al., 2017). We do not have cell lines representing the currently known TNBC subtypes (Chavez et al., 2010; Dai et al., 2017).

iii) Not all of the available BC cell lines are suitable (due to different reasons including technical easiness) for routine laboratory cultivation which narrows the range of the available *in vitro* cell model systems. The most frequently used BC cell lines are MCF7, T-47D, and MDAMB231 (Dai et al., 2017).

vi) Three dimensional (3D) cell culture systems that resemble better than monolayer (2D) cell cultures the *in vivo* biology and behavior of neoplastic formations and adequately represent the functions of 3D tissues with their extensive cell-cell and cell-matrix interactions, as well as markedly different diffusion /transport conditions have attracted the attention of the scientific community in recent years. Clinically relevant (multi)drug-resistant cell lines established *in vitro* in conditions representing the experience which oncology patients undergo during chemotherapy are also needed. They can contribute to better elucidate the molecular signaling pathways involved in drug resistance, as well as to find strategies to overcome and to identify reliable new biomarkers for response or relapse. Model systems that allow us to study the interactions between tumor cells and the immune system are also necessary (Jenkins, 2017).

Three dimensional (3D) cell cultures

Different methods and protocols for 3D cell cultures of various cancer cell lines are available. They can be also subdivided into liquid-based and scaffold-based 3D-models (Thoma et al., 2014). The most commonly used scaffold-free 3D cells cultures techniques are the forced-floating method, the hanging drop method and the agitation based method. Scaffold platforms for 3D cultures are made of synthetic or naturally-derived polymers that provide a support for cell growth and mimic extracellular matrix conditions. Various types of 3D cell culture systems have been described including:

Tumor-derived spheroids - one of the most common scaffold-free 3D cell cultures; either self-assembling or stimulated to grow as cell clusters starting from single cell suspensions; purposed for the enrichment of cancer stem cells. However, for many cancer cell lines, the efficiency

of spheroid formation is low. In addition, the production of spheroids with different sizes and shapes may influence drug efficacy and toxicity, leading to artificial results (Yamada et al., 2007; Ishiguro et al., 2017; Verjans et al., 2018).

Tumor-derived organoids – 3D constructs obtained from primary tumor tissue or developed from stem cells; epithelial cell cultures that lack a tumor stroma, vasculature, and immune cells, although involved interactions with a basal membrane (typically Matrigel) (Ishiguro et al., 2017; Xu et al., 2018). For example, 3D cancer organoids obtained from genetically engineered mouse models for BRCA1- and BRCA2-deficient cancers have been recently reported. Orthotopically implanted these organoids produce mammary tumors that recapitulate the epithelial morphology and preserve the drug response of the original tumor, can be easily genetically modified and can serve as suitable tool for investigations in the fields of tumor biology and drug resistance (Duarte et al., 2018).

Organotypic multicellular cultures attempt to maintain the native stroma and tumor heterogeneity that is lacking in organoid cell culture system – an increasing amount of data support the importance of intra-patient tumor heterogeneity and tumor-stromal interactions for cancer behaviour and response to therapy.

Multicellular tumor spheroids are 3D growing aggregates of cancer cells that more closely represent *in vivo* characteristics of the tumor microenvironment (TME). TME consists of extracellular matrix (ECM), cells (myofibroblasts, fibroblasts, neuroendocrine, adipose and immune-inflammatory cells), and the blood and lymphatic vascular networks (Chen et al., 2015) and has been suggested to play a crucial role in cancer initiation, progression, and invasion (Wang et al., 2017). Cell model systems that preserve the native TME are suitable for the evaluation of *ex vivo* drug responses as well as for investigating the role of stromal cells in cancerogenesis and especially interactions between tumor cell and immune cells.

CONCLUSION

Cell cultures have gone a long and successful way in recent decades and have become a valuable and widely used research and biotechnological tool that is also important for regenerative medicine. 2D and especially 3D breast cancer cell cultures can help us to better understand biological processes involved in this disease as well as the identification of potential therapeutic targets and diagnostic / predictive markers. In addition 3D cell cultures are suitable as a preclinical model facilitating the translation from experimental oncology and oncopharmacology to clinical practice and supporting personalized medicine.

ACKNOWLEDGEMENTS

This study was supported by Grant № ДФНИ Б 02-30 from 12.12.2014, Fund “Scientific Research”, Bulgarian Ministry of Education and Science.

REFERENCES

- A novel breast cancer cell line initially established from pleural effusion: evolution towards a more aggressive phenotype. *Int J Oncol.* 30(3): 565-72.
- Akram M, Iqbal M, Daniyal M, Khan AU (2017). Awareness and current knowledge of breast cancer. *Biol. Res.* 50(1): 33.
- Alexandrova R (2001). Tumour heterogeneity. *Exp. Pathol. Parasitol.* 4(6): 57-67.
- Alge C, Hauck S, Priglinger S, Kampik A, Ueffing M (2006). Differential protein profiling of primary versus immortalized human RPE cells identifies expression patterns associated with cytoskeletal remodeling and cell survival. *Journal Proteome Results* (5):862–878.
- Alston-Roberts C et al (2010). Cell line misidentification: the beginning of the end. *Nature Reviews Cancer* (10):441–448.
- American Cancer Society (2011). World Cancer Facts and Figures. 2nd Edition, 2011. Breast Cancer 2011. *Annals of Oncology* 22(8): 1736-1747.
- Asif H, Sultana M S, Ahmed S, Akhta N, Tariq M (2016). HER-2 Positive Breast Cancer - a Mini-Review. *Asian Pac. J. Cancer Prev.* 17(4): 1609-1615.
- Baldassarre T, Truesdell P, Craig AW (2017). Endophilin A2 promotes HER2 internalization and sensitivity to trastuzumab-based therapy in HER2-positive breast cancers. *Breast Cancer Res.* 19(1): 110.
- Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin A, Kim, S, Garraway LA (2012). The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. *Nature* 483 (7391): 603-607
- Bover L, Barrio M, Slavutsky I, Bravo AI, Quintans C, Bagnāti A, Lema B, Schiaffi J, Yomha R, Mordoh J (1991). Description of a new human breast cancer cell line, IIB-BR-G, established from a primary undifferentiated tumor. *Breast Cancer Res Treat.* 19(1): 47-56.
- Byrne AT, Alférez DG, Amant F (2017). Interrogating open issues in cancer medicine with patient-derived xenografts. *Nature Reviews Cancer* 17(10): 632.
- Cailleau R, Olivé M, Cruciger QV (1978). Long-term human breast carcinoma cell lines of metastatic origin: preliminary characterization. *In Vitro* 14(11): 911-915.
- Carranza-Rosales P, Guzmán-Delgado NE, Carranza-Torres IE, Viveros-Valdez E, Morán-Martínez J (2018). Breast Organotypic Cancer Models. *Curr Top Microbiol Immunol.* doi: 10.1007/82_2018_86.
- Chavez KJ, Garimella SV, Lipkowitz S (2010). Triple Negative Breast Cancer Cell Lines: One Tool in the Search for Better Treatment of Triple Negative Breast Cancer. *Breast Dis.* 32(1-2): 35-48.
- Chen F, Zhuang X, Lin L, Yu P, Wang Y, Shi Y, Hu G, Sun Y (2015). New horizons in tumor microenvironment biology: challenges and opportunities. *BMC Med.* 5(13):45.
- Dai X, Cheng H, Bai Z, Li J (2017). Breast Cancer Cell Line Classification and Its Relevance with Breast Tumor Subtyping. *J. Cancer* 8(16): 3131-3141.
- D'Alesio C, Bellese G, Gagliani MC, Aiello C, Grasselli E, Marcocci G, Bisio A, Tavella S, Daniele T, Cortese K, Castagnola P (2017) Cooperative antitumor activities of carnolic acid and Trastuzumab in ERBB2+ breast cancer cells. – *J. Exp. Clin. Cancer Res.* 36(1): 154.
- Domcke S, Sinha R, Levine DA, Sander C, Schultz N. (2013). Evaluating cell lines as tumour models by comparison of genomic profiles. *Nat Commun.* (4) : 2126.
- Duarte AA, Gogola E, Sachs N, Barazas M, Annunziato S, R de Ruiter J, Velds A, Blatter S, Houthuijzen JM, van de Ven M, Clevers H, Borst P, Jonkers J, Rottenberg S (2017). BRCA-deficient mouse mammary tumor organoids to study cancer-drug resistance. *Nat Methods.* 15(2):134-140.
- Eccles SA, Aboagye EO, Ali S, Anderson AS, Armes J, Berditchevski F, Blaydes JP, Brennan K, Brown NJ, Bryant HE, Bundred NJ, Burchell JM, Campbell AM, Carroll JS, Clarke RB, Coles CE, Cook GJ et al (2013). Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer. *Breast Cancer Res.* 15(5):R92.
- Edmondson R, Broglie JJ, Adcock AF, Yang L (2014). Three-dimensional cell culture systems and their applications in drug discovery and cell-based biosensors. *Assay Drug Dev. Technol.* 12(4): 207-218.
- Ethier SP, Mahacek ML, Gullick WJ, Frank N, Tja D, Weber BL (2013). Differential isolation of normal luminal mammary epithelial cells and breast cancer cells from primary and metastatic sites using selective media. *Cancer Res.* 53: 627–635.
- Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM (2010). Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. *Int. J. Cancer* 127: 2893-2917.
- Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, Forman D, Bray F (2013). Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. *Eur. J. Cancer*, 49(6): 1374-1403.
- Gazdar AF, Kurvari V, Virmani A, Gollahon L, Sakaguchi M, Westerfield M et al (1998). Characterization of paired tumor and non-tumor cell lines established from patients with breast cancer. *International Journal of Cancer* 78: 766-774.
- Gey GO, Coffman WD, Kubicek MT (1952). Tissue culture studies of the proliferative capacity of cervical carcinoma and normal epithelium. *Cancer Res.* (12): 264–265
- Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thurlimann B, Senn HJ, Panel M. (2011). Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. *Ann Oncol* (22): 1736-1747
- Hanahan D, Weinberg RA (2011). Hallmarks of Cancer: The Next Generation. *Cell* (144): 646–674.
- Holliday DL, Speirs V (2011). Choosing the right cell line for breast cancer research. *Breast Cancer Res.*, 13(4): 215.
- Hudziak RM, Lewis GD, Winget M, Fendly BM, Shepard HM, Ullrich A (1989).
- Inic Z, Zegarac M, Inic M, Markovic I, Kozomara Z, Djuricic I, Inic I, Pucic G, Jancic S (2014). Difference between Luminal A and Luminal B Subtypes According to Ki-67, Tumor Size, and Progesterone Receptor Negativity Providing Prognostic Information. *Clin. Med. Insights Oncol.* (8): 107–111.
- Ishiguro T, Ohata H., Sato A, Yamawaki K, Enomoto T. (2017). Tumor-derived spheroids: Relevance to cancer stem cells and clinical applications. *Cancer Sci.* 108(3): 283–289
- Jenkins RW, Barbie DA, Flaherty KT. (2018). Mechanisms of resistance to immune checkpoint inhibitors. *Br J Cancer.* 118(1): 9-16.
- Katt ME, Placone AL, Wong AD, Xu ZS, Searson PC (2016). In Vitro Tumor Models: Advantages, Disadvantages, Variables, and Selecting the Right Platform. *Front Bioeng. Biotechnol.* (12): 4-12.
- Koren S, Bentires-Alj M (2015). Breast Tumor Heterogeneity: Source of Fitness, Hurdle for Therapy. *Mol. Cell* 60(4): 537-546.
- Lasfargues, EY, Ozzello L (1958). Cultivation of human breast carcinomas. *J Natl Cancer Inst.* (21): 1131–1147.
- Levenson AS, Jordan VC (1997). MCF-7: the first hormone-responsive breast cancer cell line. *Cancer Res.* (57): 3071–3078.
- Levi MS, Borne RE, Williamson JS (2001). Rivest of cancer chemopreventive agents. *Curr. Med. Chem.* (8): 1349-1362.
- Longacre M, Snyder NA, Housman G, Leary M, Lapinska K, Heerboth S, Willbanks A, Sarkar S (2016). A Comparative Analysis of Genetic and Epigenetic Events of Breast and Ovarian Cancer Related to Tumorigenesis. *Int. J. Mol. Sci.* 17(5) : E759.
- Lorsch J, Collins F, Lippincott-Schwartz J (2014). Fixing problems with cell lines. *Science* 346: 1452– 1453.
- Lucey BP, Nelson-Rees WA, Hutchins GM. (2009). Henrietta Lacks, HeLa cells, and cell culture contamination. *Arch Pathol Lab Med.* 133(9):1463-7.

- Minafra S, Morello V, Glorioso F, La Fiura AM, Tomasino RM, Feo S, McIntosh D, Woolley DE (1989). A new cell line (8701-BC) from primary ductal infiltrating carcinoma of human breast. *Br. J. Cancer* 60(2): 185-192.
- Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, Clark L, Bayani N, Coppe JP, Tong F, Speed T, Spellman PT, DeVries S, Lapuk A, Wang et al NJ (2006). A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. *Cancer Cell* 10(6): 515-527.
- Nikfarjam L, Farzaneh P (2012). Prevention and Detection of Mycoplasma Contamination in Cell Culture. *Cell J.* 13(4): 203–212.
- Osborne CK (1998). Tamoxifen in the treatment of breast cancer. *N. Engl. J. Med.* 339(22): 1609-1618.
- p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. *Mol. Cell Biol.* 9(3): 1165-1172.
- Pan C, Kumar C, Bohl S, Klingmueller U, Mann M (2009). Comparative proteomic phenotyping of cell lines and primary cells to assess preservation of cell type-specific functions. *Mol Cell Proteomics* 8(8): 443–450.
- Pegram M, Hsu S, Lewis G, Pietras R, Beryt M, Sliwkowski M, Coombs D, Baly D, Kabbinavar F, Slamon D (1999). Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. *Oncogene* 18(13): 2241-2251.
- Pietras RJ, Fendly BM, Chazin VR, Pegram MD, Howell SB, Slamon DJ. (1994). Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. *Oncogene* 9(7): 1829-1838.
- Prat A. (2013). Prognostic Significance of Progesterone Receptor–Positive Tumor Cells Within Immunohistochemically Defined Luminal A Breast Cancer *J Clin Oncol.* 31(2): 203–209.
- Scherer WF, Syverton JT, Gey GO (1953). Studies on the propagation in vitro of poliomyelitis viruses. IV. Viral multiplication in a stable strain of human malignant epithelial cells (strain HeLa) derived from an epidermoid carcinoma of the cervix. *J. Exp. Med.* (97): 695–710.
- Schmidt M, Khan A, Schmidt AM, Heinze B, Hack E, Waltenberger J, Kreienberg R (2007). Sliwkowski, MX, Lofgren JA, Lewis GD, Hotaling TE, Fendly BM, Fox JA (1999). Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). *Semin. Oncol.* 26(4 Suppl 12): 60-70.
- Soule HD, Vazquez J, Long A, Albert S, Brennan M (1973). A human cell line from a pleural effusion derived from a breast carcinoma. *J. Natl. Cancer Inst.* 51(5): 1409-16.
- Subik K, Lee JF, Baxter L, Strzepek T, Costello D, Crowley P, Xing L, Hung MC, Bonfiglio T, Hicks DG, Tang P (2010). The Expression Patterns of ER, PR, HER2, CK5/6, EGFR, Ki-67 and AR by Immunohistochemical Analysis in Breast Cancer Cell Lines. *Breast Cancer (Auckl)* 10(4): 35-41.
- Thoma CR, Zimmermann M, Agarkova I, Kelm JM, Krek W (2014). 3D cell culture systems modeling tumor growth determinants in cancer target discovery. *Adv Drug Deliv Rev.* (69-70): 29-41.
- Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A (2015). Global cancer statistics 2012. *CA Cancer J Clin.* 65(2): 87-108.
- Vandewalle B, Collyn d'Hooghe M, Savary JB, Vilain MO, Peyrat JP, Deminatti M, Delobelle-Deroide A, Lefebvre J (1987). Establishment and characterization of a new cell line (VHB-1) derived from a primary breast carcinoma. *J. Cancer Res. Clin. Oncol.* 113(6): 550-558.
- Verjans ET, Doijen J, Luyten W, Landuyt B, Schoofs L (2018). Three-dimensional cell culture models for anticancer drug screening: Worth the effort? *J Cell Physiol.* 233: 2993–3003.
- Wang M, Zhao J (2017). Role of tumor microenvironment in tumorigenesis. *J Cancer.* 8(5): 761–773.
- Xu H, Lyu X, Yi M, Zhao W, Song Y, Wu K (2018). Organoid technology and applications in cancer research. *J Hematol Oncol.* 11(1):116.
- Yamada KM, Cukierman E. (2007). Modeling tissue morphogenesis and cancer in 3D. *Cell.* 130(4): 601-10.
- Zoli W, Roncuzzi L, Zini N, Lenzi L, Gruppioni R, Barzanti F, Sensi A, Amadori D, Gasperi-Campani A (1997). Establishment and characterization of two new cell lines derived from human metastatic breast carcinomas. *Breast Cancer Res. Treat.* 43(2): 141-51.